Research programme: cancer therapeutics - Myrexis

Drug Profile

Research programme: cancer therapeutics - Myrexis

Alternative Names: MPC-0767; MPI-0479605; MPI-479605; MPI-487109; MPI-487901; MPYS 197; MPYS 413

Latest Information Update: 27 Feb 2014

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Feb 2014 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPC 0767 is available for out-licensing; Myrexis does not intend to further develop the compound itself (\www.myrexis.com\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top